A Randomized, Double Blind, Parallel Group, Phase II/III, Multi-center Trial of Two Doses of ZD1839 (IressaTM) in Patients with Advanced NSCLC Who Have Failed at Least Two Previous Chemotherapy Regimens At Least One or Both Having Contained Platinum and a Taxane.

Study identifier:1839IL/0039

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Randomized, Double Blind, Parallel Group, Phase II/III, Multi-center Trial of Two Doses of ZD1839 (IressaTM) in Patients with Advanced NSCLC Who Have Failed at Least Two Previous Chemotherapy Regimens At Least One or Both Having Contained Platinum and a Taxane.

Medical condition

lung cancer

Phase

Phase 2

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Nov 2000
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria